Skip to main content


Anti-obesity medications

12-09-2020 | Liraglutide (obesity) | News

Liraglutide gets FDA go-ahead for teens with obesity

Click through to read more on this announcement

04-01-2020 | Liraglutide (obesity) | News

Liraglutide for weight loss successful in obese adolescents

Liraglutide 3.0 mg boosts weight loss in obese adolescents receiving lifestyle therapy, show the findings of a phase 3 trial.

03-11-2020 | Liraglutide (obesity) | Highlight | News

Liraglutide 3.0 mg boosts weight loss in insulin-dependent type 2 diabetes

Adding liraglutide 3.0 mg to intensive behavioral therapy increases weight loss in overweight or obese people with insulin-treated type 2 diabetes, results of the phase 3 SCALE Insulin trial show.

11-22-2019 | Liraglutide (obesity) | News

Add-on liraglutide benefits overweight insulin pump users with poor glycemic control

Adding liraglutide to continuous subcutaneous insulin infusion significantly reduces glycated hemoglobin without increasing hypoglycemia in overweight and obese people with type 1 diabetes and suboptimal glycemic control, Danish research shows.

07-18-2019 | Liraglutide (obesity) | News

Brain may put brakes on liraglutide weight loss effect

A small neuroimaging study suggests that taking liraglutide over the medium to long term may provoke a counter-regulatory response in the brain, diminishing the medication’s weight loss effect.

06-06-2019 | Liraglutide (T2DM) | News

Liraglutide may be an option for people with unresolved type 2 diabetes after metabolic surgery

Findings from the GRAVITAS trial indicate that use of the GLP-1 receptor agonist liraglutide alongside a diet and physical activity intervention may improve glycemic control among people with persistent or recurrent type 2 diabetes after bariatric surgery.

12-14-2018 | Sleep apnea | Editorial | Article

Diabetes and obstructive sleep apnea syndrome: Double trouble

Obstructive sleep apnea syndrome is a common and potentially serious comorbidity in people with diabetes and obesity. John Wilding highlights what you need to know about the condition.

10-05-2018 | Lorcaserin | EASD 2018 | News

Weight loss with lorcaserin linked to improved glycemic profile

Losing weight in the CAMELLIA-TIMI 61 trial was associated with a significantly reduced risk for developing type 2 diabetes, the investigators have reported at the 54th EASD Annual Meeting in Berlin, Germany.

08-26-2018 | Lorcaserin | Highlight | News

Neutral cardiovascular safety for lorcaserin in CAMELLIA-TIMI 61

The weight-loss medication lorcaserin neither increases nor reduces cardiovascular risk, report the CAMELLIA–TIMI 61 investigators.

08-17-2018 | Semaglutide | Highlight | News

Semaglutide shows promise for weight management

Findings from a dose-ranging phase II trial published in The Lancet suggest that semaglutide, in combination with lifestyle intervention, may aid weight loss in people with obesity who do not have diabetes.

04-13-2018 | Obesity | Review | Article

Treatment of adolescent obesity

Steinbeck KS et al. Nature Reviews Endocrinology 2018. doi: 10.1038/s41574-018-0002-8

04-03-2018 | Obesity | Review | Article

Racial disparities in obesity treatment

Byrd AS, Toth AT, Stanford FC. Curr Obes Rep 2018; Advance online publication. doi: 10.1007/s13679-018-0301-3

03-05-2018 | Obesity | Review | Article

Future pharmacotherapy for obesity: New anti-obesity drugs on the horizon

Srivastava G, Apovian C. Curr Obes Rep 2018; Advance online publication. doi: 10.1007/s13679-018-0300-4

01-05-2018 | Cardiovascular outcomes | Review | Article

Pharmacological prevention of cardiovascular outcomes in diabetes mellitus: Established and emerging agents

Saxon DR, Rasouli N, Eckel RH. Drugs 2018; 78: 203–214. doi: 10.1007/s40265-017-0857-3

10-13-2017 | Obesity | Review | Article

Current pharmacotherapy for obesity

​​​​​​​Nat Rev Endocrinol 2017; 14: 12–24. doi: 10.1038/nrendo.2017.122

11-06-2017 | Prediabetes | News

Lifestyle interventions have most staying power for diabetes prevention

A meta-analysis shows that although medications and lifestyle changes can both reduce the risk for type 2 diabetes in high-risk patients, only lifestyle modifications have a sustained effect.

08-23-2017 | Obesity | Review | Article

Weight management in patients with type 1 diabetes and obesity

Mottalib A et al. Curr Diab Rep 2017; 17: 92. doi: 10.1007/s11892-017-0918-8

07-31-2017 | Diabetes prevention | Review | Article

Pharmaceutical interventions for diabetes prevention in patients at risk

Chatterjee S, Davies M, Khunti K. Am J Cardiovasc Drugs 2017; 1: 13–24. doi: 10.1007/s40256-017-0239-y

06-23-2017 | Obesity | Review | Article

Pharmacotherapy in the management of pediatric obesity

Kelly AS, Fox CK. Curr Diab Rep 2017; 17: 55. doi: 10.1007/s11892-017-0886-z

01-18-2017 | Obesity | Review | Article

Medical management of diabesity: Do we have realistic targets?

Pappachan JM, Viswanath AK. Curr Diab Rep 2017; 17: 4. doi: 10.1007/s11892-017-0828-9

Image Credits